In this week's news roundup, we focus on skin cancer rates associated with methotrexate use, skin cancer in psoriasis cases and fatigue associated with arthritis.
A double-blind, placebo-controlled, randomized clinical trial has confirmed that low-dose methotrexate is associated with an increased risk of skin cancer, according to a study published this week in the Annals of Internal Medicine.
A systematic review and meta-analysis published today in JAMA Dermatology confirms that psoriasis patients have a slightly increased risk of cancer, specifically, keratinocyte cancer and lymphomas.
Visceral fat appears to be associated with an increased risk of musculoskeletal and widespread pain, according to researchers writing this week in Arthritis and Rheumatology. Plus, a small study shows promise in a new treatment for a rare form of pediatric lupus. This and more news in today's rheumatology news roundup.
The therapeutic management of rheumatoid arthritis has changed over the past 30 years, yet, comorbidities persist. In this quiz, we focus on findings from a new study that examines trends in clinical and patient-reported outcomes for early RA.
New treatments for rheumatoid arthritis can effectively control inflammation, but they do little to improve quality of life indicators—like fatigue—that are important to patients, shows a new study.
Long-term use of tumor necrosis factor inhibitors (TNFi) may show radiographic progression benefit in axial spondyloarthritis, say researchers recently writing in Arthritis & Rheumatology.
In this slideshow we highlight some key facts about the use of supplements to prevent fracture in women and men over the age of 50. Existing treatment guildelines recommend a combination approach with vitamin D and calcium, but some clinical trials are not entirely in agreement. Learn more in this slideshow.
The practice of systematically tapering biological disease modifying antirheumatic drugs (bDMARDs) in all patients with inflammatory arthritis who have reached a certain disease activity target may not be supported by current evidence, according to a review published recently in Autoimmunity Reviews
The internationally recommended Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) cutoff of four and above may not be applicable when initiating treatment with the tumor necrosis factor alpha inhibitor (TNFi) golimumab (Simponi, Janssen), say researchers recently writing in The Journal of Rheumatology.